Cite
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
MLA
Peterlin, Pierre, et al. “Azacitidine in Patients Older than 80 Years with Acute Myeloid Leukaemia or Myelodysplastic Syndromes: A Report on 115 Patients.” British Journal of Haematology, vol. 190, no. 3, Aug. 2020, pp. 461–64. EBSCOhost, https://doi.org/10.1111/bjh.16680.
APA
Peterlin, P., Cluzeau, T., Jullien, M., Ngo Nloga, A., Calleja, A., Angeli, E., Chevallier, P., Guillaume, T., Garnier, A., Le Bourgeois, A., Le Gouill, S., Fenaux, P., Adès, L., & Bally, C. (2020). Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. British Journal of Haematology, 190(3), 461–464. https://doi.org/10.1111/bjh.16680
Chicago
Peterlin, Pierre, Thomas Cluzeau, Maxime Jullien, Anne‐Marie Ngo Nloga, Anne Calleja, Eurydice Angeli, Patrice Chevallier, et al. 2020. “Azacitidine in Patients Older than 80 Years with Acute Myeloid Leukaemia or Myelodysplastic Syndromes: A Report on 115 Patients.” British Journal of Haematology 190 (3): 461–64. doi:10.1111/bjh.16680.